Stock Track | ADMA Biologics Plunges 26.88% After-Hours on Earnings Miss and Withdrawn Long-Term Guidance

Stock Track05-07

ADMA Biologics shares plummeted 26.88% in after-hours trading on Wednesday, following the release of the company's first quarter 2026 financial results.

The specialty biologics maker reported Q1 revenue of $114.5 million, falling short of the $141.8 million analyst consensus estimate. Adjusted net income for the quarter was $40.7 million, also missing expectations of $48.4 million. The company cited a 54% year-over-year decline in BIVIGAM revenue, driven by increased competition and distributor ordering variability, as a primary factor pressuring its topline results.

In a significant development, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. The company provided fiscal year 2026 revenue guidance of $530 million to $560 million and adjusted EBITDA guidance of $265 million to $300 million, but the removal of longer-term outlook contributed to investor concerns about future growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120249587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 04:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120249587","market":"hk","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Plunges 26.88% After-Hours on Earnings Miss and Withdrawn Long-Term Guidance","media":"Stock Track","content":"<p>ADMA Biologics shares plummeted 26.88% in after-hours trading on Wednesday, following the release of the company's first quarter 2026 financial results.</p><p>The specialty biologics maker reported Q1 revenue of $114.5 million, falling short of the $141.8 million analyst consensus estimate. Adjusted net income for the quarter was $40.7 million, also missing expectations of $48.4 million. The company cited a 54% year-over-year decline in BIVIGAM revenue, driven by increased competition and distributor ordering variability, as a primary factor pressuring its topline results.</p><p>In a significant development, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. The company provided fiscal year 2026 revenue guidance of $530 million to $560 million and adjusted EBITDA guidance of $265 million to $300 million, but the removal of longer-term outlook contributed to investor concerns about future growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Plunges 26.88% After-Hours on Earnings Miss and Withdrawn Long-Term Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Plunges 26.88% After-Hours on Earnings Miss and Withdrawn Long-Term Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 04:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics shares plummeted 26.88% in after-hours trading on Wednesday, following the release of the company's first quarter 2026 financial results.</p><p>The specialty biologics maker reported Q1 revenue of $114.5 million, falling short of the $141.8 million analyst consensus estimate. Adjusted net income for the quarter was $40.7 million, also missing expectations of $48.4 million. The company cited a 54% year-over-year decline in BIVIGAM revenue, driven by increased competition and distributor ordering variability, as a primary factor pressuring its topline results.</p><p>In a significant development, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. The company provided fiscal year 2026 revenue guidance of $530 million to $560 million and adjusted EBITDA guidance of $265 million to $300 million, but the removal of longer-term outlook contributed to investor concerns about future growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1120249587","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120249587","pubTimestamp":1778100226,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics shares plummeted 26.88% in after-hours trading on Wednesday, following the release of the company's first quarter 2026 financial results.The specialty biologics maker reported Q1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"个股追踪|ADMA Biologics盘后暴跌26.88%，因盈利未达预期并撤回长期指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics shares plummeted 26.88% in after-hours trading on Wednesday, following the release of the company's first quarter 2026 financial results.The specialty biologics maker reported Q1 revenue of $114.5 million, falling short of the $141.8 million analyst consensus estimate. Adjusted net income for the quarter was $40.7 million, also missing expectations of $48.4 million. The company cited a 54% year-over-year decline in BIVIGAM revenue, driven by increased competition and distributor ordering variability, as a primary factor pressuring its topline results.In a significant development, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. The company provided fiscal year 2026 revenue guidance of $530 million to $560 million and adjusted EBITDA guidance of $265 million to $300 million, but the removal of longer-term outlook contributed to investor concerns about future growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120249587","isCrawlerRequest":true}